Special Issue

Autologous and allogenic use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM)

Submission Deadline: 30 September 2021
Articles: 1
Special Issue Editor
Guest Editor
Dr. Pietro Gentile
Surgical Science Department, University “Tor Vergata”, Rome, Italy
Expertise: Regenerative plastic surgery
Special Issue Information

Dear Colleagues,

Adipose-derived Mesenchymal Stem Cells (AD-MSCs), and Stromal vascular Fraction (SVF) in which they are contained, are cell-based therapy strategies to improve tissue regeneration or to repair tissue defects. In particular, Stem Cells (Mesenchymal and Follicular), Biotechnology and Bioactive Molecules (Platelet-Rich Plasma (PRP), Micrografts), and Stromal vascular Fraction may be helpful in this field.

In light of current knowledge on Mesenchymal Stem Cells (MSCs), AD-MSCs, epithelial and dermal cells, Human Follicle Mesenchymal Stem Cells (HF-MSCs), and Stromal Vascular Fraction (SVF), numerous researchers have developed different strategies to improve the effects of these varied biotechnology applications.

This Special Issue aims to collect multidisciplinary submissions of original research articles that demonstrate basic research and clinical impacts of autologous and/or allogeneic MSCs, AD-MSCs, and SVFs in tissue repair. Review articles that describe the current state of the art are also welcomed.

Potential topics include but are not limited to:

• The molecular mechanisms of SVF, AD-MSCs and MSCs during regeneration;

• Therapeutic application of SVF, AD-MSCs and MSCs (allogeneic and autologous) for major diseases and clinical conditions such as regenerative plastic surgery;

• MSCs and engineered MSCs as vehicles for drug delivery.

Dr. Pietro Gentile

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at https://jour.ipublishment.com/bri by registering and logging into this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.

Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and written in clear, concise English and should contain all essential data in order to make the presentation clear and the results of the study replicable. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see


Autologous Stromal Vascular Fraction, Allogeneic Stromal Vascular Fraction, Autologous Adipose-Derived Mesenchymal Stem Cells, Allogeneic Adipose-Derived Mesenchymal Stem Cells, Allogeneic and autologous Mesenchymal Stem Cells
Share This Special Issue
Published Papers (1 papers)
Open Access

A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis

Panayiota Petrou, Ibrahim Kassis, Nour Eddine Yaghmour, Ariel Ginzberg, Dimitrios Karussis
Frontiers in Bioscience-Landmark Volume 26 Issue 10, pp.693-706
Managing Editor: Graham Pawelec
DOI: 10.52586/4980 Published: 30 October 2021